AstraZeneca succeeds in treating lupus in late-stage study

World

AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study.

The company logo for pharmaceutical company AstraZeneca is displayed on a screen on the floor at the New York Stock Exchange (NYSE) in New York, U.S., April 8, 2019. REUTERS/Brendan McDermid

Share this content

Bookmark

REUTERS: AstraZeneca Plc said on Monday its experimental treatment significantly reduced disease activity in patients with autoimmune disorder lupus, in a late-stage study.

The results pit the British drugmaker's anifrolumab against rival GlaxoSmithKline Plc's Benlysta – the only new drug approved for lupus in the last 60 years.

Advertisement

Advertisement

Benlysta recorded 473 million pounds of global sales in 2018, up 26per cent from a year earlier.

In the trial of 365 patients on standard therapy for moderate-to-severe systemic lupus erythematosus (SLE), 47.8per cent of those who received anifrolumab experienced improvement in disease activity after 52 weeks of treatment, compared with 31.5per cent of patients on placebo.

SLE is a debilitating and sometimes fatal chronic inflammatory autoimmune disorder that can affect the joints, skin, heart, lungs, kidneys and brain, with about five million people affected globally, according to the Lupus Foundation of America.

More than half the patients on the intravenous treaRead More – Source